2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Quest Diagnostics company profile · diagnostic testing & information services (labs, patients, physicians) · history · financial snapshot · S&P 500 rank #342 · 奎斯特診斷公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | DGX (NYSE) |
| Company | Quest Diagnostics Incorporated |
| GICS sector / industry | Health Care (XLV) / Health Care Services |
| S&P 500 rank (by weight) | #342 · 0.04% (Nov 2, 2026) |
| Sector rank (by market cap) | #45 in Health Care (Nov 2, 2026) |
| Share price (frozen benchmark) | $251.63 (Nov 2, 2026) |
| Headquarters | Secaucus, New Jersey |
| Founded | 1967 (as Metropolitan Pathology Laboratory) |
| CEO | Jim Davis (Chairman, President and CEO) |
| Employees | about 55,000 (2025 profile) |
| Market cap | $27.77B (Nov 2, 2026) |
WHAT IT DOES
Quest Diagnostics is one of the world's largest providers of diagnostic testing and information services, running laboratories and patient service centers that test blood, urine and other samples for physicians, hospitals, employers and patients, and selling the resulting data and insights.
The model is the standard national-laboratory model: routine volume plus specialty menu, with acquisitions folding regional laboratories into the national network. FY2025 net revenues were $11,035M, up 11.8% from $9,872M, GAAP operating income was $1,556M (up 15.6% from $1,346M), adjusted operating income was $1,759M at a 15.9% margin, net income attributable was $992M, reported diluted EPS was $8.75 (up 13.8%) and adjusted diluted EPS was $9.85 (up 10.3%), with cash from operations of $1.89B.
TradingKey's $988M net-income figure is the same line rounded differently — the company-release $992M is used.
BUSINESS SEGMENTS — FY2025
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| Diagnostic Information Services | — | — | — |
| Diagnostic Solutions and other | — | — | — |
Quest's business is overwhelmingly diagnostic information services — the laboratory network itself — with diagnostic solutions and other services (including employer testing and data products) as a smaller complement. The segment table is qualitative because a revenue split is not stated in the sources used.
HISTORY
| Year | Milestone |
|---|---|
| 1967 | Metropolitan Pathology Laboratory founded |
| 1996 | Quest Diagnostics spins off from Corning |
| 2020 | Testing scales up sharply during the COVID-19 pandemic |
| 2025 | FY2025 net revenues reach $11,035M, up 11.8% |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Net revenues | $11,035M (+11.8% YoY) |
| GAAP operating income | $1,556M (+15.6% YoY) |
| Adjusted operating income (stated separately) | $1,759M (15.9% margin) |
| Net income attributable / Reported diluted EPS | $992M / $8.75 (adjusted EPS $9.85) |
| Cash from operations | $1.89B |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Quest Diagnostics is the S&P 500's other diagnostics name: at a 0.04% index weight and #45 in Health Care by market cap, it is, with the other national laboratory network, the index's exposure to laboratory testing volumes.
Its test volumes are a standing read on U.S. healthcare utilization — requisition counts move before claims data does.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 2, 2026 close) and Slickcharts S&P 500 analysis page (market cap) |
| Financials | Quest Diagnostics FY2025 results, release dated Feb 10, 2026 (fiscal year ended Dec 31, 2025), company profile sources |
| Sector classification | GICS (Health Care Services) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
FINANCIALS
公司快照
| 代碼 | DGX(NYSE) |
| 公司 | Quest Diagnostics Incorporated |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健服務 |
| 標普500排名(按權重) | #342 · 0.04%(2026 年 11 月 2 日) |
| 板塊內排名(按市值) | 醫療保健第 #45(2026 年 11 月 2 日) |
| 股價(凍結基準) | $251.63(2026 年 11 月 2 日) |
| 總部 | 美國新澤西州錫考克斯 |
| 成立 | 1967 年(前身為 Metropolitan Pathology Laboratory) |
| 行政總裁 | Jim Davis(董事長、總裁兼行政總裁) |
| 員工 | 約 55,000(2025 年簡介) |
| 市值 | $27.77B(2026 年 11 月 2 日) |
業務概覽
奎斯特診斷是全球最大的診斷檢測與資訊服務商之一,營運實驗室與病人服務中心,為醫生、醫院、僱主與病人檢測血液、尿液及其他樣本,並銷售所得數據與見解。
其模式為標準全國實驗室模式:常規銷量加專科項目,收購將地區實驗室併入全國網絡。FY2025 淨收入為 $11,035M,同比增長 11.8%(FY2024 為 $9,872M),GAAP 營業利潤為 $1,556M(同比 +15.6%,上年為 $1,346M),經調整營業利潤為 $1,759M(利潤率 15.9%),歸屬淨利潤為 $992M,申報攤薄每股收益為 $8.75(同比 +13.8%),經調整攤薄每股收益為 $9.85(同比 +10.3%),營運現金為 $1.89B。
TradingKey 報淨利潤 $988M 為同一口徑的不同四捨五入——此處用公司公告 $992M。
業務板塊 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 診斷資訊服務 | — | — | — |
| 診斷解決方案及其他 | — | — | — |
奎斯特業務絕大部分為診斷資訊服務——即實驗室網絡本身——診斷解決方案及其他服務(包括僱主檢測與數據產品)為較小的補充。板塊收入拆分未見於所用來源,故板塊表只作定性列示。
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1967 | Metropolitan Pathology Laboratory 創立 |
| 1996 | 奎斯特診斷自康寧分拆 |
| 2020 | 新冠疫情期間檢測大幅擴大 |
| 2025 | FY2025 淨收入達 $11,035M,同比增長 11.8% |
競爭地位
財務快照 — FY2025
| 淨收入 | $11,035M(同比 +11.8%) |
| GAAP 營業利潤 | $1,556M(同比 +15.6%) |
| 經調整營業利潤(分開列示) | $1,759M(利潤率 15.9%) |
| 歸屬淨利潤/申報攤薄每股收益 | $992M/$8.75(經調整每股收益 $9.85) |
| 營運現金 | $1.89B |
主要風險
對標普500的重要性
奎斯特診斷是標普500的另一診斷標的:指數權重 0.04%、醫療保健板塊市值第 #45,與另一全國實驗室網絡同為指數對實驗室檢測銷量的敞口。
其檢測銷量,是美國醫療使用量的常設讀數——檢測申請數往往先於理賠數據變動。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 2 日收盤)及 Slickcharts 標普500分析頁(市值) |
| 財務 | 奎斯特診斷 FY2025 業績,2026 年 2 月 10 日公告(財政年度截至 2025 年 12 月 31 日)、公司簡介來源 |
| 板塊分類 | GICS(醫療保健服務),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 13:20 · updated 2026-11-14 23:17 · rev 5